China’s CanSino says gets green light to continue Phase III trials

China’s CanSino Biologics Inc said on Monday an independent committee found the drugmaker’s COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of …
( read original story …)